Life Sciences

Life-sciences companies grow best in locations that can combine qualities like a good business environment, skilled workers, strong research universities, and available capital. Strengthening these and related factors can give states a stronger competitive advantage.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
February 12, 2018
Life-sciences companies grow best in locations that can combine qualities like a good business environment, skilled workers, strong research universities, and available capital. Strengthening these and related factors can give states a stronger competitive advantage.
September 12, 2017
In a presentation to a roundtable gathering of international think tanks in New York City, Stephen Ezell argued we are entering an era of renewed biomedical innovation marked by a wide range of new-to-the-world treatments for cancers, rare and chronic diseases, and other disorders.
August 31, 2017
President Widodo promised a renewed focus on innovation and economic growth. But his government has undermined its own strategic goals by badly weakening intellectual property laws that are critical for innovative industries are to thrive.
June 14, 2017
ITIF submitted comments to the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service on its proposed revisions to regulations governing crops improved through biotechnology.
June 14, 2017
ITIF submitted comments to the Food and Drug Administration on how they should regulate foods derived from gene-edited plants.
June 6, 2017
For more than two decades, the Prescription Drug User Fee Act (PDUFA) has underpinned America’s leadership in biopharmaceutical innovation. Join ITIF for a discussion with policy experts, industry leaders, and patient advocates to discuss why a timely reauthorization of PDUFA is critical to the future of medical innovation.
February 27, 2017
PDUFA enables a safe, timely, and efficient process of drug evaluation while applying best practices in regulatory science that support America’s global leadership in biomedical innovation.
July 14, 2016
The UN high-level access to medicines panel must consider the complete range of factors impacting access to medicines, writes Stephen Ezell in Innovation Files.
July 12, 2016
In Innovation Files, Stephen Ezell provides an overview of localization barriers to trade in the life sciences sector recently enacted by countries around the world.
July 11, 2016
Spurring biopharmaceutical innovation to understand and cure brain diseases and disorders could improve health outcomes for more than 50 million Americans while increasing GDP by up to $1.5 trillion or more.

Pages